Navigation Links
ChromaDex Names Pharmaceutical Industry Veteran William F. Spengler as President

IRVINE, Calif., Oct. 28 /PRNewswire-FirstCall/ -- ChromaDex Corporation (OTC Bulletin Board: CDXC), a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property, announced today that the Company appointed William F. Spengler to President of the Company, effective November 15, 2010. Mr. Spengler brings a strong and diversified background to the position, having held leadership roles in pharmaceutical companies such as Guilford Pharmaceuticals, MGI Pharma, and Bristol-Myers Squibb as well as Endo Pharmaceuticals where he currently serves as a Director. In his new role, Mr. Spengler will have responsibility for the expansion and implementation of the company's strategy as ChromaDex increases its leadership position in the natural products industry.

"Bill has demonstrated success in his previous positions both in pharmaceutical and non-pharmaceutical industries," said Frank Jaksch, CEO and co-founder of ChromaDex. "He has strong strategic and general management skills, combined with vast experience working in the public markets. We believe that this experience will be extremely important in support of the growth of the Company."

"The natural products and phytochemical industry holds extraordinary growth potential," said Spengler. "ChromaDex has both the scientific base and the strong and growing portfolio of licensed compounds necessary to enable it to become a market leader across an array of potential distribution channels. I am enthusiastic about the opportunity this asset combination presents, and I look forward to working with Frank, the ChromaDex executive team and board to move this business forward."

Mr. Spengler is currently the Executive Vice President, Chief Financial Officer, and Treasurer of Smith & Wesson Holding Corporation, a position he will be completing prior to joining ChromaDex on November 15. Mr. Spengler was previously the Executive Vice President and Chief Financial Officer of MGI PHARMA, Inc. from April 2006 until January 2008, and was Senior Vice President, International & Corporate Development of MGI PHARMA from October 2005 to April 2006. From July 2004 to October 2005, Mr. Spengler was Executive Vice President and Chief Financial Officer of Guilford Pharmaceuticals Inc. prior to its acquisition by MGI PHARMA in October 2005. From May 2002 to June 2004, Mr. Spengler was President, Chief Operating Officer and director of Osteoimplant Technology, Inc. Mr. Spengler was previously a Vice President of Finance at Black & Decker, and prior to that spent 14 years in various finance, planning and business development positions at Bristol Myers Squib. Mr. Spengler currently serves on the Board of Directors of Endo Pharmaceuticals, a publicly traded pharmaceutical company. He holds a BA in Economics from Yale University and an MBA from New York University's Stern School of Business.

About ChromaDexChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. Among other things, the Company is currently focusing on clinical studies and the commercialization of its new product, pTeroPure™ pterostilbene ( as a result of its exclusive worldwide patent rights for pterostilbene. For more information, visit or follow ChromaDex on Twitter @ChromaDex.

Forward-Looking StatementsAny statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.Investor InquiriesLiviakis Financial Communications, Inc.John M. Liviakis, President415-389-4670John@Liviakis.comChromaDex Contact Jenny RoblesAdministrative Assistant to the CEO10005 Muirlands Blvd, Suite G, Irvine, CA 92618949-419-0288jennyr@chromadex.comMedia ContactMegan LavineCanale Communications3033 5th Ave., Suite 400, San Diego, CA

SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Commences a Clinical Trial on pTeroPure™ Pterostilbene
2. ChromaDex Launches pTeroPure Pterostilbene
3. ChromaDex Announces 2008 Year End Financial Results
4. ChromaDex Announces Second Quarter 2008 Financial Results
5. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
6. Castle Access Names New Managing Director
7. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
8. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
9. RF Technologies® Names Mark Harwood New President
10. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 2010
11. and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Domain Development Conference
Post Your Comments:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:6/7/2016)... 7, 2016  Syngrafii Inc. and San Antonio ... that includes integrating Syngrafii,s patented LongPen™ eSignature "Wet" ... collaboration will result in greater convenience for SACU ... while maintaining existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):